China Universal Asset Management »

Revance Therapeutics shares owned by China Universal Asset Management

Quarter-by-quarter ownership of Revance Therapeutics (RVNC) shares owned by China Universal Asset Management from 13F filings

Historical chart of China Universal Asset Management investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by China Universal Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by China Universal Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $84k 17k 4.95
2023-12-31 $89k 10k 8.76
2023-09-30 $26k 2.3k 11.56
2023-06-30 $28k 1.1k 25.41
2023-03-31 $36k 1.1k 32.09
2022-12-31 $15k 836 17.94
2022-09-30 $18k 684 26.32

More positions owned by China Universal Asset Management

Microsoft Corp Common Stock (MSFT)
Nvidia Corp Common Stock (NVDA)
Amazon.com Common Stock (AMZN)
Meta Platforms Inc-class A Common Stock (META)
Vertex Pharmaceuticals Common Stock (VRTX)
Amgen Common Stock (AMGN)
Servicenow Common Stock (NOW)
Gilead Sciences Common Stock (GILD)
Regeneron Pharmaceuticals Common Stock (REGN)
Alphabet Inc-cl A Common Stock (GOOGL)
Adobe Common Stock (ADBE)
Broadcom Common Stock (AVGO)
Visa Inc-class A Shares Common Stock (V)
Apple Common Stock (AAPL)
Uber Technologies Common Stock (UBER)

View all positions for China Universal Asset Management

Top funds holding Revance Therapeutics

Palo Alto Investors
Vanguard Group
Franklin Resources
Jpmorgan Chase & Co
Bamco
Walleye Trading Advisors
Goldman Sachs Group
Rice Hall James & Associates
Charles Schwab Investment Management
Citadel Advisors
Wellington Management Company
D. E. Shaw & Co
HighTower Advisors
Balyasny Asset Management
Barclays

View all funds holding Revance Therapeutics